Biozone Pharmaceuticals, Inc.
Formerly International Surf Resorts Inc.
Biozone Pharmaceuticals, Inc. is listed today as Cocrystal Pharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 6 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2017 | $3 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Sep 2016 | $4 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Mar 2016 | $5 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jan 2014 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Oct 2013 | $4 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Aug 2013 | $2 M | Private placement after listing | $2 to $10 million | options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Biozone Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2017).
SEC Form D · May 2017
The industry group it chose in its notices: Other.
SEC Form D · May 2017
That is all the official record says: Biozone Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Biozone Pharmaceuticals, Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Frost Gamma Investments Trust | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Gary Wilcox | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Opko Health, Inc. | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Roger D. Kornberg | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Sam Lee | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Steven D. Rubin | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Cocrystal Pharma, Inc. shares, as of Sep 30, 2026.
- Vanguard Capital Management LLC$0 M1.86%
- Renaissance Technologies LLC$0 M0.91%
- Two Sigma Investments, LP$0 M0.74%
- Geode Capital Management, LLC$0 M0.65%
- Vanguard Fiduciary Trust Co$0 M0.42%
- BlackRock, Inc.$0 M0.38%
- Citadel Advisors LLC$0 M0.22%
- Neuberger Berman Group LLC$0 M0.17%
- State Street Corp$0 M0.11%
- Parallel Advisors, LLC$0 M0.07%
- Northern Trust Corp$0 M0.06%
- XTX Topco Ltd$0 M0.06%
- Tower Research Capital LLC (TRC)$0 M0.03%
- Wells Fargo & Company/mn$0 M0.03%
- Nuveen, LLC$0 M0.01%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Gary Wilcox | Executive officer | May 2017 |
| James F. Martin | Executive officer | May 2017 |
| Sam F. Lee | Executive officer | May 2017 |
| Curtis F. Dale | Executive officer | Sep 2016 |
| Walt Addison Linscott | Executive officer | Sep 2016 |
| Curtis A Dale | Executive officer | Mar 2016 |
| Douglas L Mayers | Executive officer | Mar 2016 |
| Jeffrey A Meckler | Executive officer | Mar 2016 |
| Sam A Lee | Executive officer | Mar 2016 |
| Gerald McGuire | Executive officer | Jan 2014 |
| Sam Lee | Executive officer | Jan 2014 |
| Brian M. Keller | Executive officer | Nov 2013 |
| Elliot M. Maza | Executive officer | Nov 2013 |
| Christian M. Oertle | Chief Strategy Officer | Sep 2013 |
| David S. Block | Director | May 2017 |
| Gary Wilcox | Director | May 2017 |
| Jane H. Hsiao | Director | May 2017 |
| Phillip S. Frost | Director | May 2017 |
| Raymond F. Schinazi | Director | May 2017 |
| Steven D. Rubin | Director | May 2017 |
| David S Block | Director | Mar 2016 |
| Gary A Wilcox | Director | Mar 2016 |
| Jane H Hsiao | Director | Mar 2016 |
| Jeffrey A Meckler | Director | Mar 2016 |
| Phillip A Frost | Director | Mar 2016 |
| Raymond F Schinazi | Director | Mar 2016 |
| Steven D Rubin | Director | Mar 2016 |
| Jane Hsiao | Director | Jan 2014 |
| Phillip Frost | Director | Jan 2014 |
| Roger Kornberg | Director | Jan 2014 |
| Sam Lee | Director | Jan 2014 |
| Steven Rubin | Director | Jan 2014 |
| Brian M. Keller | Director | Nov 2013 |
| Elliot M. Maza | Director | Nov 2013 |
| Roberto M. Prego-Novo | Director | Nov 2013 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.